83% of participants on an oral Sirturo-containing regimen achieved a favorable outcome compared to 71% of patients on the control...

Patients on pemvidutide experienced only 21.9% of weight loss attributable to lean mass. Pemvidutide preserves muscle tissue and prioritizes fat...

Tagrisso is the first-line therapy for patients whose lung cancer tumors have EGFR exon 19 deletions or exon 21 substitution...

The subcutaneous injectable version of Rybrevant significantly reduced the risk of death compared to intravenous Rybrevant when used in combination...

ETH47, a nasally administered mRNA drug candidate was safe,well-tolerated by healthy participants, and did not result in any clinically relevant...

Patients with familial chylomicronemia syndrome (FCS) treated with plozasiran demonstrated a maximum reduction of 98% in triglyceride levels at month...

As a 2nd line therapy for multiple myeloma, Carvykti can lower the risk of disease progression or death by 59%...

Mezagitamab achieved a sustained platelet response and symptomatic relief in patients treated for chronic ITP. Mezagitamab showed a favorable safety...

Patients with pancreatitis on high-dose Auxora showed a 2.1-day improvement in time to solid food tolerance compared to the placebo...

Capvaxive covers roughly 84% of serotypes responsible for pneumococcal disease in adults 50 years and older. Capvaxive is non-inferior to...